References
- Shah N, Tam C, Seymour JF, et al. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma 2014 Sep 11. [Epub ahead of print]
- Ferrario A, Pulsoni A, Olivero B, et al.Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. Cancer 2012;118:3954–3961.
- Tomás JF, Montalbán C, De Sevilla AF, et al. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leuk Lymphoma 2011;52:409–416.
- Tucci A, Martelli M, Rigacci L, et al. Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B cell lymphoma: a prospective multicenter evaluation on 173 patients by the Lymphoma Italian Foundation (FIL). Leuk Lymphoma 2014 Aug 11. [Epub ahead of print]
- Bocchia M, Bigazzi C, Marconcini S, et al. Favorable impact of low dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment of low grade non Hodgkin lymphoma. Haematologica 1999;84:716–720.
- Marotta G, Bigazzi C, Lenoci M, et al. Low dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia Haematologica 2000;85:1268–1270.
- Fabbri A, Lenoci M, Gozzetti A, et al. Low dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. Hematol J 2004;5:472–474.
- Fabbri A, Lenoci M, Gozzetti A, et al. Low dose fludarabine plus cyclophosphamide as first line treatment in elderly patients with indolent non-Hodgkin lymphoma. Br J Haematol 2007;139:90–93.
- Gozzetti A, Candi V, Fabbri A, et al. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia. Leuk Res 2014;38:891–895.